Department of Pulmonary Medicine, Koç University Faculty of Medicine, İstanbul, Turkey; Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA, USA; Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Cardiology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey.
Anatol J Cardiol. 2023 Jul 3;27(7):375-389. doi: 10.14744/AnatolJCardiol.2023.3307. Epub 2023 Jun 7.
Obstructive sleep apnea is common in adults with cardiovascular disease. Accumulating evidence suggests an association between obstructive sleep apnea and cardiovascular disease independent of the traditionally recognized cardiovascular disease risk factors. Observational studies indicate that obstructive sleep apnea is a risk factor for development of cardiovascular disease and that alleviation of obstructive events with positive airway pressure may improve cardiovascular disease outcomes. However, recent randomized controlled trials have not supported the beneficial effect of positive airway pressure in cardiac populations with concomitant obstructive sleep apnea. Some evidence suggests that the relationship between obstructive sleep apnea and traditionally recognized cardiovascular disease risk factors is bidirectional, suggesting that patients with cardiovascular disease may also develop obstructive sleep apnea and that efficient treatment of cardiovascular disease may improve obstructive sleep apnea. Recent data also indicate that the apnea-hypopnea index, which is commonly used as a diagnostic measure of obstructive sleep apnea severity, has limited value as a prognostic measure for cardiovascular disease outcomes. Novel markers of obstructive sleep apnea-associated hypoxic burden and cardiac autonomic response seem to be strong predictors of adverse cardiovascular disease outcomes and response to treatment of obstructive sleep apnea. This narrative review and position paper from the Turkish Collaboration of Sleep Apnea Cardiovascular Trialists aims to update the current evidence about the relationship between obstructive sleep apnea and cardiovascular disease and, consequently, raise awareness for health professionals who deal with cardiovascular and respiratory diseases to improve the ability to direct resources at patients most likely to benefit from treatment of obstructive sleep apnea and optimize treatment of the coexisting cardiovascular diseases. Moreover, the Turkish Collaboration of Sleep Apnea Cardiovascular Trialists aims to contribute to strengthening the efforts of the International Collaboration of Sleep Apnea Cardiovascular Trialists in this context.
阻塞性睡眠呼吸暂停在患有心血管疾病的成年人中很常见。越来越多的证据表明,阻塞性睡眠呼吸暂停与心血管疾病之间存在关联,而这种关联独立于传统上公认的心血管疾病危险因素。观察性研究表明,阻塞性睡眠呼吸暂停是心血管疾病发展的一个危险因素,使用正压通气缓解阻塞性事件可能改善心血管疾病结局。然而,最近的随机对照试验并不支持正压通气在伴有阻塞性睡眠呼吸暂停的心脏人群中的有益效果。一些证据表明,阻塞性睡眠呼吸暂停与传统上公认的心血管疾病危险因素之间的关系是双向的,这表明患有心血管疾病的患者也可能患上阻塞性睡眠呼吸暂停,而有效地治疗心血管疾病可能会改善阻塞性睡眠呼吸暂停。最近的数据还表明,作为阻塞性睡眠呼吸暂停严重程度诊断指标的呼吸暂停低通气指数作为心血管疾病结局的预后指标价值有限。阻塞性睡眠呼吸暂停相关缺氧负担和心脏自主反应的新标志物似乎是不良心血管疾病结局和对阻塞性睡眠呼吸暂停治疗反应的强有力预测指标。土耳其睡眠呼吸暂停心血管试验协作组的这篇叙述性综述和立场文件旨在更新关于阻塞性睡眠呼吸暂停与心血管疾病之间关系的现有证据,从而提高处理心血管和呼吸系统疾病的卫生专业人员的认识,以便能够将资源集中在最有可能受益于阻塞性睡眠呼吸暂停治疗的患者身上,并优化对并存的心血管疾病的治疗。此外,土耳其睡眠呼吸暂停心血管试验协作组旨在为加强国际睡眠呼吸暂停心血管试验协作组在这方面的努力做出贡献。